The Mediator complex subunit MED15,a promoter of tumour progression and metastatic spread in renal cell carcinoma

Abstract

BACKGROUND/OBJECTIVE:

MED15 is a part of the multiprotein Mediator complex which is involved in the transcription of polymerase (Pol) II-dependent genes. Several studies in this field have reported altered expressions of distinct subunits in human malignancy. However, the role of MED15 in renal cell carcinoma (RCC) has not be investigated yet.

METHODS:

First, we performed an RNA expression and survival analysis of MED15 in RCC by using the database cBioPortal. To confirm these data on the protein level, we executed immunohistochemical (IHC) staining against MED15 on a tissue microarray containing 184 samples of the most common subtypes of the tumour at the various stages. Further, we performed functional analysis including proliferation, migration, and invasion assays on the RCC cell lines A-498 and ACHN following the siRNA-mediated MED15 knockdown.

RESULTS:

On the mRNA level, higher expression of MED15 was associated with worse patient survival rates. IHC staining validated this tendency, unfortunately the results were not significant. However, supporting this tendency, in vitro-assays showed a significant decrease in proliferation, migration, and invasion after knockdown of MED15.

CONCLUSION:

The research concludes that MED15 does seem to play a tumour promoting role in the progression and metastatic spread of renal cell carcinoma.

Keywords

Mediator complex renal cell carcinoma MED15 tumour promoter

1. Introduction

In Germany, renal cell carcinoma (RCC) was the sixth and tenth most common malignancy in men and women respectively, in 2012. Approximately 15,000 people, two-thirds of whom were men and one third women, were diagnosed with RCC that led to approximately 5,200 deaths in 2012. In addition, approximately 90% of all renal tumours in adulthood are RCC, which are classified into several different subtypes based on histomorphological features [1]. The most common subtype is clear cell RCC (ccRCC), followed by papillary RCC (pRCC) and chromophobe RCC (chRCC). In each RCC subtype, distinctive genetic alterations are involved in the development and progression of renal cancer, although the carcinogenic pathways remain to be fully elucidated. Clear cell RCC (ccRCC) was associated with VHL alterations, whereas papillary RCC (pRCC) contained MET mutations. Increased knowledge about the genetic changes led to the development of novel prognostic, diagnostic, and therapeutic targets for this disease [2].

MED15 is a part of the multiprotein Mediator complex, which functions as a bridge between regulatory proteins and RNA polymerase II (Pol II), thereby regulating the Pol II-dependent transcription. It can be divided into four modules – head, middle, tail, and kinase – and is comprised of $\approx$ 33 subunits in humans. Interestingly, MED15 is a subunit of the tail and essential for transforming growth factor- $\beta$ (TGF- $\beta$ )/Smad2/3 signal transduction [3, 4, 5, 6, 7]. Several studies have reported altered expressions of distinct subunits in human malignancies [8, 9]. For example, $M$ ED15 overexpression has been described in about 70% of local-recurrent and distant metastatic castration-resistant prostate cancer (CRPC), in contrast to no or low frequencies in androgen-sensitive PCa and in benign tissue [10, 11]. In head and neck squamous cell carcinoma [HNSCC], MED15 was overexpressed in 35% of primary tumours, 30% of lymph node metastases, and 70% of recurrences in contrast to no or low expression in benign tumours [12]. Additionally, MED23 was frequently upregulated in human hepatocellular carcinoma (HCC) tissues compared to non-tumour liver tissues [13].

However, the tumour promoter role of MED15 in the progression of renal cell carcinoma (RCC) has not been investigated yet, which establishes the importance of conducting this research.

2. Material and methods

2.1 Ethics statement

This investigation was conducted in accordance with ethical standards, the Declaration of Helsinki, and national and international guidelines. Ethical approval for using human material in the present study was obtained from the Internal Review Board of the University Hospital of Bonn (IRB# 036/08). The participants of the study agreed in writing beforehand and were anonymised before inclusion in the study cohort.

2.2 RNA expression analysis by cBioPortal

The database cBioPortal for Cancer Genomics (http://cbioportal.org, Version 1.4.0) was utilised to investigate the mRNA expression of MED15 in ccRCC extended by a survival analysis. The cBioPortal data-base provides a Web resource for exploring, visualizing, and analysing multidimensional cancer genomics data. The portal reduces molecular profiling data from cancer tissues and cell lines into readily understandable genetic, epigenetic, gene expression, and proteomic events [14, 15]. For the analysis, RNA sequencing data from “The Cancer Genome Atlas” (TCGA) [16] were used (RNA Seq V2 RSEM) with two SDs from the mean and a threshold of $\pm$ 2.0. The mRNA z-scores were precomputed from the expression values and compared to the expression distribution of each gene in tumours that are diploid for this gene [14]. Two mRNA analyses for ccRCC, named “Kidney Renal Clear Cell Carcinoma TCGA, Nature 2013” and “Kidney Renal Clear Cell Carcinoma TCGA, Provisional”, are available on cBioPortal with 392 and 446 samples respectively. The investigation further sub-entities of RCCs (like pRCC or chRCC) did not reveal any trends or statistical significance (data not shown).

2.3 Tissue microarray construction

The kidney cohort used in this study, provided by the Clinic for Urology of the University Hospital Bonn, contained 24 benign samples, 108 ccRCC samples, 28 pRCC samples, 10 chromophobe samples, and 14 metastases derived by ccRCC; in total, $n=$ 184 (Table 1).

Table 1
Clinical pathological data of the kidney cohort

	RCC	ccRCC	pRCC	chRCC	Metastasis	Benign
	$\Sigma=$ 146(%)	$\Sigma=$ 108(%)	$\Sigma=$ 28(%)	$\Sigma=$ 10(%)	$\Sigma=$ 14(%)	$\Sigma=$ 24(%)
Sex
Male	100 (68.5)	69 (63.9)	25 (89.3)	6 (60.0)	12 (85.7)	17 (70.8)
Female	46 (31.5)	39 (36.1)	3 (10.7)	4 (40.0)	2 (14.3)	7 (29.2)
Age
Mean	61.89	62.15	60.29	63.20	60.64	57.93
Median	63.00	63.00	63.00	69.50	61.50	61.00
Range	26–85	26–85	35–82	27–85	41–76	28–80
TNM
T1	68 (46.6)	45 (41.7)	17 (60.7)	6 (60.0)	–	–
T2	35 (24.0)	25 (23.1)	6 (21.4)	4 (40.0)	–	–
T3	42 (28.8)	37 (34.3)	5 (17.9)	–	–	–
T4	1 (0.7)	1 (0.9)	–	–	–	–
N+	8 (5.5)	7 (6.5)	1 (3.6)	–	–	–
M+	15 (10.3)	12 (11.1)	3 (10.71)	–	–	–
Cancer associated death	8 (5.5)	7 (6.5)	1 (3.6)	–	–	–
Relapse	24 (16.4)	22 (20.4)	2 (7.1)	–	–	–
Grading
G1	44 (30.1)	33 (30.6)	11 (39.3)	–	–	–
G2	87 (59.6)	72 (66.7)	15 (53.6)	–	–	–
G3	5 (3.4)	3 (2.8)	2 (7.1)	–	–	–

RCC $=$ renal cell carcinoma, ccRCC $=$ clear cel RCC, pRCC $=$ papillary RCC, chRCC $=$ chromophoe RCC.

Tissue microarrays (TMA) were performed as described previously [17, 18]. To explain in brief, formal-in-fixed paraffin-embedded (FFPE) tissues were cut into 4- $\mu$ m-thick sections and mounted on slides. After staining with haematoxylin and eosin (H&E), relevant areas of benign tissue and primary tumour were identified and circled by a pathologist. Each tumour and corresponding benign region was represented with up to three cores, measuring 0.6 mm in diameter on a TMA recipient block using a semiautomatic tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). H&E TMA sections were assessed again to confirm the histology.

2.4 MED15 protein expression analysis by immunohistochemistry (IHC)

Prior to performing IHC analyses in the selected TMAs, the specificity of the antibody was confirmed according to the manufacturer’s instructions by using non-seminomatous germ cell tumour (NSGCT) as a positive control. IHC was performed using the Ventana Benchmark automated staining system (Ventana Medical System, Tuscon, AZ, USA). Briefly, slides were incubated with the primary antibody according to the manufacturer’s instructions – anti-MED15 rabbit polyclonal (1:50, clone 11566-1-AP, Proteintech, Chicago, IL) at room temperature; antibody dilution was conducted using a Ventana diluent. For signal detection, the ultraView Universal DAB detection kit (Ventana Medical System, Tuscon, AZ, USA) was utilised. Finally, slides were counterstained with haematoxylin and bluing reagent, dehydrated, and mounted.

After IHC was performed, the staining was evaluated independently by two pathologists (GK, TM). Only cases with at least one assessable TMA core with sufficient tumour tissue were included in the analysis. Nuclear protein expression was evaluated and quantified according a score ranging between 0 $=$ no expression to 3 $=$ high expression. The cut-off used to determine a nuclear MED15 overexpression ( $\geqslant$ 2) was consistently set above the expression of benign samples.

2.5 Clinical data and statistics

Associations with clinical-pathological parameters were established. Survival analysis was evaluated by the Kaplan-Meier estimator and log rank tests. Statistical evaluation was performed using the Student’s t-test in Microsoft Excel and SPSS. The data were analysed anonymously.

2.6 Cell lines and culture conditions

Renal cell carcinoma (RCC) cell lines ACHN and A-498 were purchased from the American Type Culture Collection (ATCC ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ , Manassas, VA) and were grown in a 5% CO ${}_{2}$ incubator at 37 ${}^{\circ}$ C and 85% humidity. Monolayer cultures were maintained in the RPMI1640 medium (Biochrom) supplemented with 10% heat-inactivated foetal calf serum (FCS, Sigma, St. Louis, MO), 1% streptomycin-penicillin antibiotics (Gibco ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ ), and 1% glutamine (Thermo-Scientific Fisher, Darmstadt, Germany).

2.7 SiRNA-mediated MED15 knockdown

MED15 siRNA (sc-75767, Santa Cruz, TX, USA) is a pool of three target-specific siRNAs designed to knockdown gene expression. A non-targeting scrambled siRNA was employed as a negative control (Exiqon Life Sciences, Copenhagen, Denmark). Renal cell carcinoma (RCC) cell lines ACHN and A-498 were transfected with 100 nmol/L siRNA using Screenfect A (Genaxxon Bioscience GmbH, Ulm, Germany) for 48 and 72 hours respectively.

2.8 Western blot

Post transfected cells were washed with ice-cold phosphate buffered saline (PBS) and lysed in a protein extraction buffer for 30 minutes. In addition, samples were sonicated for 2 minutes and subsequently centrifuged at 16,000 $\times$ g for 30 minutes at 4 ${}^{\circ}$ C. Protein concentration was measured utilising the bicinchoninic acid (BCA) Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA), fractionated by the SDS-Page and transferred to a nitrocellulose membrane. After incubation with 5% non-fat milk in TBST (50 mM Tris, 150 mM NaCl, 0.05% Tween 20. pH 7.5) for 60 minutes, the membrane was incubated with anti-MED15 rabbit polyclonal (1:500, clone 11566-1-AP, Proteintech, Chicago, IL) or anti-GAPDH rabbit monoclonal (1:2000, clone 14C10, Cell Signaling Technology, Danvers, MA) primary antibodies at 4oC overnight. Then, the membrane is washed three times for 5 minutes with TBST and incubated with horseradish peroxidase conjugated anti-rabbit antibody for 1 hour at room temperature. Staining was detected using the SuperSignal West Femto Maximum Sensitivity Substrate, an ultra-sensitive enhanced chemiluminescent (ECL) substrate (Thermo Fisher Scientific, Waltham, MA).

2.9 Quantitative reverse transcription PCR (qRT-PCR)

RNA was isolated from cell line pellets using the Total RNA Purification Mini Spin Column Kit (Genaxxon Bioscience GmbH, Ulm, Germany). RNA quantity and quality was analysed using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). cDNA was synthesised using 200 ng total RNA and the PrimeScript RT Reagent Kit with gDNA Eraser (Takara Bio, Saint-Germain-en-Laye, France). Quantitative real-time PCR was performed using 5 ng/ $\mu$ l cDNA, Takara Bio SYBR Premix Ex Taq II with ROX Plus, and 10 pmol/ $\mu$ l forward and reverse primer. The following primer sequences were used – MED15 (Forward: 5’-TTGAGGATGATGAGCGGC AG-3’, Reverse: 5’-GGAGGTCCTTGTCATCCAGC-3’) and ß-Actin (Forward: 5’-CCAACCGCGAGAAG ATGA-3’, Reverse: 5’-CCAGAGGCGTACAGGGAT AG-3’). The PCR technique was performed utilising an ABIPrism 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Data were analysed using Qbase+ (Biogazelle, Ghent, Belgium) with $\beta$ -Actin (ACTB) as the reference gene by applying the 2- $\Delta\Delta$ CT algorithm.

2.10 EZ4U cell proliferation assay

The EZ4U cell proliferation assay kit was used according to the manufacturer’s protocol (EZ4U; Biom-edica Group, Vienna, Austria). In brief, the siRNA transfections for proliferation assays were performed in 96-well plates. In each well of a flat-bottom 96-well plate, either 1.2 $\times$ 10 ${}^{4}$ cells (A-498) or 2.0 $\times$ 10 ${}^{4}$ cells (ACHN) were seeded in a 200 $\mu$ l cell culture medium. SiRNA-mediated MED15 knockdown was then performed and cells were incubated to adhere and grow for 72 hours. After incubation, 20 $\mu$ l of EZ4U substrate solutions were added before incubating again for 3 hours (A-498) and 4 hours (ACHN) until the colour of the solution changed from yellow to orange, which is based on the ability of living cells to reduce uncoloured tetrazolium salts to coloured formazan derivatives. The absorbance was measured using a microplate reader (Tecan, Model Spectra Thermo) at 450 nm wavelength. Each experiment was repeated at least three times.

2.11 Migration assays

The siRNA transfections for migration assays were performed in 6-well plates. Forty-eight hours post transfection, cells were trypsinised and seeded into migration Boyden chambers. 5 $\times$ 10 ${}^{4}$ cells were plated in the upper chamber of migration inserts (VWR, Darmstadt, Germany) containing 0% FCS medium. The lower chamber was filled with medium containing 10% FCS for chemotactic attraction. After 24 hours, RCC cells were fixed with 4% paraformaldehyde (Merck, Darmstadt, Germany), stained with haematoxylin (Waldeck, Münster, Germany), and washed with water. Membranes were scanned and manually evaluated by counting the migrated cells in four randomly selected fields. Each experiment was repeated at least three times.

2.12 Invasion assays

The siRNA transfections for invasion assays were performed in 6-well plates. Forty-eight hours post transfection, cells were trypsinised and seeded into Matrigel invasion chambers. 1 $\times$ 10 ${}^{5}$ cells were plated in the upper chamber of invasion inserts (VWR, Darmstadt, Germany) containing 0% FCS medium. The lower chamber was filled with medium containing 10% FCS for chemotactic attraction. After 24 hours, RCC cells were fixed with 4% paraformaldehyde (Merck, Darmstadt, Germany), stained with haematoxylin (Waldeck, Münster, Germany), and washed with water. Membranes were scanned and manually evaluated by counting the invaded cells in four randomly selected fields. Each experiment was repeated at least three times.

3. Results

3.1 Transcriptional expression of the MED15 by cBioPortal

Using the cBioPortal database, we analysed the mRNA expression of MED15 in clear cell renal cell carcinoma (ccRCC) samples. In two analyses, 392 and 446 samples of ccRCC were investigated. The results of the expression analyses are shown in Fig. 1A and those for survival and disease-free survival in Fig. 1B–D.

Figure 1.

Transcriptional expression analysis of MED15 in ccRCC extended by the survival analysis. To investigate the mRNA expression [RNA Seq V2 RSEM] of MED15 in clear cell renal cell carcinoma (ccRCC), the database cBioPortal for Cancer Genomics was utilized. Two mRNA analyses for ccRCC, named “Kidney Renal Clear Cell Carcinoma TCGA, Nature 2013” and “Kidney Renal Clear Cell Carcinoma TCGA, Provisional”, are available on cBioPortal with 446 and 392 samples respectively. The expression is given in % divided into “upregulation”, “downregulation”, and “no alteration” (A). MED15 overexpression is associated with strongly reduced overall survival (B $+$ C) and disease-free survival (D) in ccRCC patients.

Figure 2.

IHC staining of MED15 in RCC. Representative IHC images from tissue of benign kidney, ccRCC, pRCC, and chRCC analysis of the MED15 protein expression. Whole core 10x and inserts 40x objective magnification. Quantification of nuclear protein expression according a score of 0 $=$ no expression to 3 $=$ high expression and a cut-off of $\geqslant$ 2 was determined as a MED15 overexpression.

3.1.1 Transcriptional expression regarding the database cBioPortal

In the first analysis, named “Kidney Renal Clear Cell Carcinoma TCGA, Nature 2013” an alteration of MED15 is described in 7% (26/391) of the samples. In detail, 23 upregulations and three downregulations of MED15 mRNA expression were detected.

Next, we investigated the datasheet called “Kidney Renal Clear Cell Carcinoma TCGA, Provisional” and found out that MED15 is altered in 7% (29/445) of the cases. In total, 23 upregulations and six downregulations of MED15 mRNA expression were found (Fig. 1A).

3.1.2 Survival analysis regarding transcriptional expression

In the analysis titled “Kidney Renal Clear Cell Carcinoma TCGA, Nature 2013”, cases with alteration in MED15 (predominantly overexpressed) displayed a significantly reduced overall survival rate [ $p\leqslant$ 0.001; cases with alteration (28.81 months) vs. cases without alteration (76.98 months)] (Fig. 1B). Data of the disease-free survival do not exist.

In the investigation titled “Kidney Renal Clear Cell Carcinoma TCGA, Provisional”, cases with alteration in MED15 (predominantly overexpressed) displayed a significantly worse overall survival rate [ $p\leqslant$ 0.001; cases with alteration (36.5 months)] in comparison to cases without alteration (116.75 months) (Fig. 1C). In addition, altered expression of MED15 presented a significantly unfavourable disease-free survival rate [ $p=$ 0.015; cases with alteration (61.63 months) vs. cases without alteration (123.72 months)] (Fig. 1D).

In conclusion, the investigation of the database cBioPortal showed that patients overexpressing MED15 suffer from a substantially worse disease outcome in comparison to no overexpression of MED15.

3.2 Immunohistochemistry and functional investigations

To validate the transcriptional data obtained from the analysis of the cBioPortal database, we performed protein (IHC) and functional analyses on a tissue microarray (TMA) cohort with the available clinical information and cell lines.

Immunohistochemical (IHC) staining shows MED15 nuclear expression in benign renal tissue, papillary RCC (pRCC), clear cell RCC (ccRCC), chromophobe RCC (chRCC), and metastases derived from ccRCC (Fig. 2). In addition, a MED15 cytoplasmic expression seemed to not be specific. We found MED15 to have a significantly higher expression in pRCC (median nuclear staining intensity $=$ 1.0, SD $=$ 0.876) compared to ccRCC (median nuclear staining intensity $=$ 0.5, SD $=$ 0.742, $p=$ 0.007); however, compared to benign renal tissue, the difference was not as significant (median nuclear staining intensity $=$ 1.0, SD $=$ 0.381, $p=$ 1.000). Additionally, the expression of MED15 was absent or low in benign tissue and even lower in ccRCC. Nevertheless, in the latter, the range of expression was larger than in benign tissue (Fig. 3A). However, the small number of events should be taken into account. Moreover, ccRCC patients overexpressing MED15 showed a tendency towards a worse clinical outcome and decreased survival (Fig. 3B $+$ C) (cancer-specific survival $p=$ 0.729, progression-free survival $p=$ 0.546). Furthermore, MED15 expression did not associate with TNM stage and grading in ccRCC and pRCC (data not shown). In the latter, we found no correlation between the expression of MED15 and survival (Fig. S1A $+$ B). For chRCC histopathological and survival data were insufficient.

Figure 3.

MED15 expression profile and survival analysis based on the MED15 expression in RCC. MED15 protein expression profile of the total kidney cohort including benign tissue, ccRCC, pRCC, and chRCC (A). ${}^{**}p<$ 0.01. Kaplan-Meier analysis for cancer-specific survival (B) and progression free survival (C) according to the MED15 expression in ccRCC. MED15 overexpression (expression $\geqslant$ 2 nuclear staining intensity) shows a nonsignificant tendency towards a worse disease outcome in ccRCC patients.

To investigate the functional role of the subunit MED15 in progression and metastatic spread, we performed an in vitro siRNA mediated-knockdown of MED15 in the ccRCC cell lines A-498 and ACHN (Fig. 4A–C). Thereafter, we compared the measured proliferative activity of scrambled control and MED15 knockdown of cells and observed a significant decrease in A-498 ( $p=$ 0.008) and ACHN ( $p\leqslant$ 0.001) (Fig. 4D). Further, migration and invasion were significantly reduced in A-498 ( $p\leqslant$ 0.001) and ACHN ( $p\leqslant$ 0.001) cells following the transient MED15 knockdown as compared to scrambled control cells (Fig. 4E–H).

In conclusion, high MED15 expression showed a nonsignificant tendency towards an unfavourable outcome in ccRCC. Further, the MED15 knockdown led to reduced malignant behaviour in the primary ccRCC cell line A-498 and the metastatic ACHN.

4. Discussion

The Mediator complex serves as a hub for pathway activation and specific gene expression, and recent studies identified distinct subunits of the Mediator to be involved in different malignancy types, including RCC. For example, MED8 has been described to be frequently overexpressed in RCC and was associated with parameters of worse outcome and decreased survival rates [8, 9].

Figure 4.

MED15 knockdown reduces progression and metastatic spread in ccRCC. Reduced MED15 expression in A-498 and ACHN cells treated with MED15 specific siRNA are shown by qPCR (A) and western blot (B $+$ C). MED15 knockdown led to significantly reduced proliferation (D), migration (E $+$ F), and invasion (G $+$ H) in the ccRCC cell lines A-498 and ACHN. 4x and 10x objective magnification. ${}^{**}p\leqslant$ 0.01, ${}^{***}p\leqslant$ 0.001.

In this study, we investigated whether the Mediator complex subunit MED15, which is essential for TGF- $\beta$ /Smad2/3 signalling pathway, is implicated in renal cell carcinoma (RCC) [7, 10]. The transcriptional expression analysis of the database cBioPortal showed a significantly worse overall and disease-free survival rate for ccRCC patients overexpressing MED15 thus defining a lethal phenotype. In our survival analysis of the IHC, MED15 overexpression showed a nonsignificant tendency towards worse disease outcome in ccRCC patients. This is slightly different from the results of the mRNA analysis, which clearly and significantly shows that a MED15 overexpression is associated with a worse survival. Here, however, the difference in size between the cohorts and the associated low number of events for the overall survival ( $n=$ 7) and the progression free survival ( $n=$ 22) must be discussed. For the mRNA analysis cohorts with 392 and 446 samples were used, while the IHC cohort consists of 184 samples. It is to be assumed that with a larger cohort strength in the IHC analysis, the results would show not only a tendency, but a significance. Thus, our investigation can be viewed as a first screening study with convincing results.

Supporting our findings, Shaikhibrahim et al. reported that MED15 expression was found to be increased by TGF- $\beta$ activation, such that MED15 knockdown affected phosphorylation and shuttling of p-Smad2/3 to the nucleus and TGF- $\beta$ -enhanced proliferation [7, 10] The above findings led us to perform an in vitro-assays on the ccRCC cell lines A-498 and ACHN which were significantly impaired in proliferation, migration, and invasion following siRNA-mediated MED15 knockdown.

In our investigation, we found an entity-specific MED15 expression profile, especially MED15 that had a significantly higher expression in pRCC compared to ccRCC, although an overexpression of MED15 in pRCC has no influence in the survival analysis. These subtype specific differences might be due to the divergent genetic background including the inactivation of the Von-Hippel-Lindau (VHL) gene, which is specific to ccRCC and is not found in other histological variants, such as papillary RCC [2]. The VHL tumour suppressor gene is located at the short arm of chromosome 3 (3p) and inactivated in VHL disease and in sporadic cases of ccRCC. The pVHL (protein VHL) is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF) as well as in other cellular pathways, such as assembly of extracellular matrix (ECM) and stabilisation of p53 and Jade-1 [19]. Papillary RCC (pRCC) has two main subtypes – type 1, which was associated with MET alteration or gain of chromosome 7, whereas type 2 was characterized by increased expression of the NRF2-antioxidant response element (ARE) pathway [20].

Targeted therapy is a growing part of the treatment for many types of cancer. Despite the very promising studies on the role of MED15 in the different tumor entities [10, 11, 12], no inhibitor of MED15 has been developed so far. For the subunit CDK8 and its paralog CDK19, however, this has already been successfully achieved with the development of Senexin B [21]. The use of Senexin B resulted in a suppressed tumour growth or augmented the effects of the estrogen receptor (ER) antagonist fulvestrant in ER-positive breast cancer xenografts. These results identify CDK8 as a novel downstream mediator of ER and suggest the utility of CDK8 inhibitors for ER-positive breast cancer therapy [21]. Due to the comprehensive results it is very likely, an inhibitor for MED15 will be developed promptly and available for investigations. For use in cancer therapy, however, not only the inhibition alone of MED15 must be considered, but possibly also in combination with agents of the participating signaling cascades, e.g. TGF- $\beta$ /Smad2/3 [7, 10, 11].

In conclusion, we found MED15 to have a frequently higher expression in pRCC compared to ccRCC, and it seems to be a promoter of tumour progression and metastatic spread in renal cell carcinoma.

Footnotes

Acknowledgments

The study was supported by the Ferdinand Eisenberger Fellowship of the German Society of Urology (DGU) (SYI1/FE-13) and the Maria von Linden-Program of the University of Bonn for IS.

Conflict of interest

We declare no conflict of interest.

Supplementary data

Supplement 1.

Survival analysis based on the MED15 expression in pRCC. Kaplan-Meier analysis for cancer-specific survival (A) and progression free survival (B) according to the MED15 expression in pRCC. No correlation between the expression of MED15 and survival.

References

Robert Koch Institut in Deutschland 2011/2012 10, Ausgabe 2015, Zentrum für Krebsregisterdaten Gesundheitsberichterstattung des Bundes.

Yap

N.Y.

et al., Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms, BioMed Research International (2015), 476508.

Malik

and Roeder

R.G.

, The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation, Nature Reviews. Genetics 11(11) (2010), 761–772.

Cai

et al., Mediator Structural Conservation and Implications for the Regulation Mechanism, Structure 17(4) (2009), 559–567.

Ansari

S.A.

and Morse

R.H.

, Mechanisms of Mediator complex action in transcriptional activation, Cellular and Molecular life Sciences 70(15) (2013), 2743–2756.

Boube

et al., Evidence for a Mediator of RNA Polymerase II Transcriptional Regulation Conserved from Yeast to Man, Cell 110(2) (2002), 143–151.

Kato

et al., A component of the ARC/Mediator complex required for TGF beta/Nodal signalling, Nature 418 (2002), 641–646.

Syring

et al., Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types, Oncotarget 7(17) (2016), 23043–23055.

Schiano

et al., Involvement of Mediator complex in malignancy, Biochimica et Biophysica Acta 1845(1) (2014), 66–83.

10.

Shaikhibrahim

et al., MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer, International Journal of Cancer 135(1) (2014), 19–26.

11.

Offermann

et al., MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signalling, Oncotarget 8(5) (2017), 7964–7976.

12.

Shaikhibrahim

et al., Clinical and Molecular Implications of MED15 in Head and Neck Squamous Cell Carcinoma, The American Journal of Pathology 185(4) (2015), 1114–1122.

13.

Guo

et al., Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma, Journal of Gastroenterology and Hepatology 30(6) (2015), 1094–1103.

14.

Gao

et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Science Signaling 6(269) (2013), pl1.

15.

Cerami

et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discovery 2(5) (2012), 401–404.

16.

Tomczak

Czerwińska

and Wiznerowicz

, The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge, Contemporary Oncology (Pozna Poland) 19(1A) (2015), A68–A77.

17.

Scheble

V.J.

et al., ERG rearrangement in small cell prostatic and lung cancer, Histopathology 56(7) (2010), 937–943.

18.

Scheble

V.J.

et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor, Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 23(8) (2010), 1061–1067.

19.

Nyhan

M.J.

O’Sullivan

G.C.

and McKenna

S.L.

, Role of the VHL (von Hippel–Lindau) gene in renal cancer: a multifunctional tumour suppressor, Biochemical Society Transactions 36(Pt 3) (2008), 472–478.

20.

The Cancer Genome Atlas Research Network, Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma, The New England Journal of Msedicine 374(2) (2016), 135–145.

21.

McDermott

M.S.

et al., Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer, Oncotarget 8(8) (2017), 12558–12575.

The Mediator complex subunit MED15,a promoter of tumour progression and metastatic spread in renal cell carcinoma

Abstract

BACKGROUND/OBJECTIVE:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Material and methods

2.1 Ethics statement

2.2 RNA expression analysis by cBioPortal

2.3 Tissue microarray construction

Table 1 Clinical pathological data of the kidney cohort

2.5 Clinical data and statistics

2.6 Cell lines and culture conditions

2.7 SiRNA-mediated MED15 knockdown

2.8 Western blot

2.9 Quantitative reverse transcription PCR (qRT-PCR)

2.10 EZ4U cell proliferation assay

2.11 Migration assays

2.12 Invasion assays

3. Results

3.1 Transcriptional expression of the MED15 by cBioPortal

3.1.2 Survival analysis regarding transcriptional expression

3.2 Immunohistochemistry and functional investigations

Footnotes

Acknowledgments

Conflict of interest

Supplementary data

References

Table 1
Clinical pathological data of the kidney cohort